BRPI0416305A - método de seleção, método de determinação se um paciente mamìfero diagnosticado com cáncer é propenso a beneficiar-se do tratamento com antagonista de tgf-beta, método de tratamento de destruição ou perda óssea, métodos de tratamento de paciente mamìfero e kit que compreende um recipiente - Google Patents

método de seleção, método de determinação se um paciente mamìfero diagnosticado com cáncer é propenso a beneficiar-se do tratamento com antagonista de tgf-beta, método de tratamento de destruição ou perda óssea, métodos de tratamento de paciente mamìfero e kit que compreende um recipiente

Info

Publication number
BRPI0416305A
BRPI0416305A BRPI0416305-2A BRPI0416305A BRPI0416305A BR PI0416305 A BRPI0416305 A BR PI0416305A BR PI0416305 A BRPI0416305 A BR PI0416305A BR PI0416305 A BRPI0416305 A BR PI0416305A
Authority
BR
Brazil
Prior art keywords
treatment
mammalian patient
tgf
benefit
present
Prior art date
Application number
BRPI0416305-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Ellen H Filvaroff
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0416305A publication Critical patent/BRPI0416305A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
BRPI0416305-2A 2003-11-13 2004-11-04 método de seleção, método de determinação se um paciente mamìfero diagnosticado com cáncer é propenso a beneficiar-se do tratamento com antagonista de tgf-beta, método de tratamento de destruição ou perda óssea, métodos de tratamento de paciente mamìfero e kit que compreende um recipiente BRPI0416305A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52039803P 2003-11-13 2003-11-13
US55795104P 2004-03-31 2004-03-31
PCT/US2004/036651 WO2005050200A2 (en) 2003-11-13 2004-11-04 Screening assays and methods of tumor treatment

Publications (1)

Publication Number Publication Date
BRPI0416305A true BRPI0416305A (pt) 2007-01-09

Family

ID=34623132

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416305-2A BRPI0416305A (pt) 2003-11-13 2004-11-04 método de seleção, método de determinação se um paciente mamìfero diagnosticado com cáncer é propenso a beneficiar-se do tratamento com antagonista de tgf-beta, método de tratamento de destruição ou perda óssea, métodos de tratamento de paciente mamìfero e kit que compreende um recipiente

Country Status (13)

Country Link
US (1) US20060015952A1 (cg-RX-API-DMAC7.html)
EP (1) EP1682890A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007515949A (cg-RX-API-DMAC7.html)
KR (1) KR20060127409A (cg-RX-API-DMAC7.html)
AR (1) AR046832A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004292180A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0416305A (cg-RX-API-DMAC7.html)
CA (1) CA2542215A1 (cg-RX-API-DMAC7.html)
IL (1) IL174916A0 (cg-RX-API-DMAC7.html)
NO (1) NO20062715L (cg-RX-API-DMAC7.html)
RU (1) RU2006120483A (cg-RX-API-DMAC7.html)
TW (1) TW200526957A (cg-RX-API-DMAC7.html)
WO (1) WO2005050200A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053682A2 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7412026B2 (en) * 2004-07-02 2008-08-12 The Board Of Regents Of The University Of Oklahoma Phase-contrast x-ray imaging systems and methods
US20080082367A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082359A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of State Of Delaware Computational systems for biomedical data
US7853626B2 (en) 2006-09-29 2010-12-14 The Invention Science Fund I, Llc Computational systems for biomedical data
US10546652B2 (en) * 2006-09-29 2020-01-28 Gearbox Llc Computational systems for biomedical data
US8122073B2 (en) 2006-09-29 2012-02-21 The Invention Science Fund I Computational systems for biomedical data
US10503872B2 (en) 2006-09-29 2019-12-10 Gearbox Llc Computational systems for biomedical data
US20080091730A1 (en) * 2006-09-29 2008-04-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10068303B2 (en) 2006-09-29 2018-09-04 Gearbox Llc Computational systems for biomedical data
US20080082583A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080109484A1 (en) * 2006-09-29 2008-05-08 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10095836B2 (en) * 2006-09-29 2018-10-09 Gearbox Llc Computational systems for biomedical data
US8491890B2 (en) * 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
NZ623273A (en) 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
RU2012107535A (ru) * 2009-07-30 2013-09-10 Антисенс Фарма Гмбх КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β
WO2011053743A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
EP3117709B1 (en) * 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013173827A2 (en) 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
KR101479543B1 (ko) * 2013-03-15 2015-01-07 서강대학교산학협력단 Tfg-tec 융합 컨스트럭트를 이용한 종양 질환의 예방 또는 치료용 물질의 스크리닝 방법 및 이의 용도
JP6805428B2 (ja) 2014-04-27 2021-01-06 フェイムウェイヴ リミテッド Ceacam1に対するヒト化抗体
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3356512B1 (en) 2015-10-02 2021-03-31 Wake Forest University Health Sciences, Inc. Methods and apparatus for modeling cancer metastasis in vitro
EP3368571B1 (en) * 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
JP7763450B2 (ja) 2018-02-02 2025-11-04 ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズ 免疫療法に関するオルガノイドならびにそれを調製および使用する方法
KR102917630B1 (ko) 2018-08-21 2026-01-27 앨버트 아인슈타인 컬리지 오브 메디신 인간 Tim-3에 대한 모노클로날 항체
US12260607B2 (en) 2018-12-15 2025-03-25 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
WO2001057061A1 (en) * 2000-02-04 2001-08-09 California Pacific Medical Center Research Institute Novel use of ribozymes to block gene expression
US20010046502A1 (en) * 2000-02-04 2001-11-29 The Board Of Trustees Of The University Of Illinois Animal model for testing immunotherapies of spontaneous metastatic disease
CA2298737A1 (en) * 2000-02-10 2001-08-10 Manikkam Suthanthiran 2167334tgf-.beta. antagonists to inhibit tumor cell formation or progression
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta

Also Published As

Publication number Publication date
JP2007515949A (ja) 2007-06-21
RU2006120483A (ru) 2007-12-20
TW200526957A (en) 2005-08-16
AU2004292180A1 (en) 2005-06-02
WO2005050200A9 (en) 2005-08-18
AU2004292180A2 (en) 2005-06-02
WO2005050200A2 (en) 2005-06-02
NO20062715L (no) 2006-08-11
KR20060127409A (ko) 2006-12-12
EP1682890A2 (en) 2006-07-26
WO2005050200A3 (en) 2005-12-01
CA2542215A1 (en) 2005-06-02
IL174916A0 (en) 2006-08-20
US20060015952A1 (en) 2006-01-19
AR046832A1 (es) 2005-12-28

Similar Documents

Publication Publication Date Title
Ristow et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
RU2006120483A (ru) Скрининг-анализы и способы лечения опухоли
BRPI0518307A2 (pt) mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3
ATE268477T1 (de) Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit
Ho et al. Protein kinase Mζ is necessary for cocaine-induced synaptic potentiation in the ventral tegmental area
Imai et al. A missense mutation in the SH3BP2 gene on chromosome 4p16. 3 found in a case of nonfamilial cherubism
Cerwenka et al. Treatment of patients with pyogenic liver abscess
Borofsky et al. Initial experience and comparative efficacy of the UreTron: a new intracorporeal ultrasonic lithotriptor
Kawaragi et al. Teriparatide does not exacerbate bone metastases in breast cancer bone metastasis model
BRPI0512336A (pt) métodos de diagnósticos para osteoporose
Kitao et al. Alpha-fetoprotein in serum and tumor tissues in dogs with hepatocellular carcinoma
Betz et al. The immunohistochemical analysis of fibronectin, collagen type III, laminin, and cytokeratin 5 in putrified skin
RU2207573C2 (ru) Способ прогнозирования продолжительности жизни больных печеночно-клеточной карциномой
WO2022241292A3 (en) Use of markers in the diagnosis and treatment of parkinson's disease
Getman et al. Infections of muscle, joint, and bone
Parikh et al. Effect of non-surgical therapy on gingival crevicular fluid aspartate aminotransferase levels in chronic periodontitis patients: A biochemical study
Muhammedoğlu et al. Safety and efficacy of laparoscopic colectomy in low volume centre following effective laparoscopic trai ning. Retrospective cohort study
Soong et al. Further analysis of Soong grade and flexor tendon complications
Hedberg et al. Peri-anastomotic microdialysis lactate assessment after esophagectomy
RU2519342C2 (ru) Способ диагностики травматического и нетравматического происхождения гнилостно измененных спаек
Silva et al. Subcutaneous solitary fibrous tumor: A case report
Saito et al. Cat Bite-Associated Infections of the Upper Extremity Requiring Surgical Treatment: A Report of Two Cases Involving Pasteurella multocida and Capnocytophaga felis
Hasenauer et al. Wound Infections
RU2082970C1 (ru) Способ оценки воздействия электромагнитного поля на регенерацию костной ткани при чрескостном остеосинтезе

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.